At JPM, Biogen CEO tries to take down the deal temperature - BioPharma Dive
While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his company to go after larger deals.
Biogen
Business Services · Massachusetts, United States · 7,570 Employees
View Company Info for Free
About
Headquarters
225 Binney St, Cambridge, Massachusetts, 02142,...Phone Number
(617) 679-2000Website
www.biogen.comRevenue
$9.6 BillionStock Symbol
BIIBIndustry
Most Recent Scoops
Dec 11 2024
Project
reported that Skyclaris has currently reached 30-35% market penetration and expects to eventually achieve 70-75% peak penetration, in line with rare disease benchmarks. The company maintains its $1 billion peak sales target but acknowledges it will take time to identify remaining patients.
Dec 11 2024
Project
Biogen has announced key priorities under new CEO Chris Viehbacher, including reducing costs by $1 billion by 2025, reprioritizing R&D, and launching products like Leqembi, Skyclaris, and Zurzuvae. The company aims to evolve its strategy and position for future growth through these initiatives and recent acquisitions.
Who is Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refRead more
Biogen Org Chart
Is Biogen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Biogen launches new products
Funding: Get notified immidiatlly once Biogen has new funding data
Check if Biogen has recently received funding, and reach out quickly before it becomes old news!
Biogen, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Biogen is spiking on competitors!
Earning: See what the market has to say on Biogen recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Biogen
Click to see if Biogen had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Biogen as Masked Content
Find more new buyers
Compare Similar Companies to Biogen
Compare insights from companies similar to Biogen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Biogen
$9.6B
7.6K
Biogen Email Formats
Biogen uses at least 5 email formats with first.last (ex. John.Smith@biogen.com) being used 81.7% of the time
| Biogen Email Formats | Percentage | |
|---|---|---|
| first.last | John.Smith@biogen.com | 81.7% |
| first.last | John.Smith@biogenidec.com | 3.7% |
| first + last | JohnSmith@biogen.com | |
| first_last | John_Smith@biogen.com | |
| first | John@biogen.com | |
Get Verified Emails
View Email Formats for Biogen
Biogen Employee Growth Rate
View Biogen’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Biogen Tech Stack
A closer look at the technologies used by Biogen
Most Recent Scoops
Dec 11 2024
Project
reported that Skyclaris has currently reached 30-35% market penetration and expects to eventually achieve 70-75% peak penetration, in line with rare disease benchmarks. The company maintains its $1 billion peak sales target but acknowledges it will take time to identify remaining patients.
Sales, Pharmaceuticals
Dec 11 2024
Project
Biogen has announced key priorities under new CEO Chris Viehbacher, including reducing costs by $1 billion by 2025, reprioritizing R&D, and launching products like Leqembi, Skyclaris, and Zurzuvae. The company aims to evolve its strategy and position for future growth through these initiatives and recent acquisitions.
Product Launch, Pharmaceuticals, Corporate Strategy
Dec 11 2024
Project
Biogen announced that its Skyclaris (omaveloxolone) launch has reached a global sales run rate of around $300 million, with approximately 1,500 patients on therapy out of 4,500-5,000 total U.S. prevalence. The company is using AI and field teams to identify new Friedrich's ataxia patients and still aims for $1 billion peak sales potential.
Sales, Pharmaceuticals, Artificial Intelligence
Dec 11 2024
Project
highlighted key dynamics for Leqembi's launch, including the importance of the 6-month mark for physician and patient feedback, expanding infusion capacity through AIC partnerships, and new prescribers starting with 1-2 patients. The company noted significant runway for growth given the large patient population.
Pharmaceuticals, Healthcare Operations, Operations
Dec 11 2024
Project
Sales, Pharmaceuticals
Biogen News & Media
Biogen Inc. (BIIB) Appoints New Chief Accounting Officer - GuruFocus
Biogen Inc. (BIIB) has announced the appointment of Sean Godbout as Vice President, Chief Accounting Officer, and Global Corporate Controller, effective MarchBiogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB) J.P.Biogen Announces New Chief Accounting Officer Appointment - TipRanks.com
Biogen ( ($BIIB) ) has issued an update. On January 13, 2025, Biogen Inc. announced the appointment of Sean Godbout as Vice President, Chief Accounting Officer & Gl...FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option TOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and...
Read more news
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM t... Read More
